PARP1 and neoplasm: It is also the best-studied protein in the PARP family since monotherapy with PARP-1 inhibitors selectively kills tumours harbouring deficiencies in BRCA1 and BRCA2 genes, which are involved in homologous recombination DNA repair pathway12.